EUVIMEDEUVIMED entdecken
Open Access

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, Todd Yezefski, Michael C Haffner, Heather H Cheng, Robert B Montgomery, Michael T Schweizer, Evan Y Yu, Peter S Nelson, Delphine L Chen, Amir Iravani

Journal of Nuclear Medicine · 07.11.2024 · jnumed.124.267665

DOI: 10.2967/jnumed.124.267665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.11.2024. Verfasst von Ridvan Arda Demirci und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Lutetium, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingLutetiumSingle Photon Emission Computed Tomography Computed TomographyDipeptidesNeoplasm MetastasisHumansMaleAgedRetrospective StudiesTreatment OutcomeAged, 80 and overProstate-Specific AntigenMiddle Aged

Stichwörter der Autor:innen

PSMA radiopharmaceutical therapySPECT/CTnew lesionsradionuclide therapyresponse assessmenttumor volume

Substanzen

Heterocyclic Compounds, 1-RingLutetiumDipeptidesPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, University of Washington, Seattle, Washington.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington; and.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.

Förderung

  • NCI NIH HHS

Zitieren

APA

Demirci, R. A., Gulati, R., Hawley, J. E., Yezefski, T., Haffner, M. C., Cheng, H. H., Montgomery, R. B., Schweizer, M. T., Yu, E. Y., Nelson, P. S., Chen, D. L., & Iravani, A. (2024). SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617. Journal of Nuclear Medicine, jnumed.124.267665. https://doi.org/10.2967/jnumed.124.267665

Vancouver

Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, et al. SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617. Journal of Nuclear Medicine. 2024:jnumed.124.267665. doi:10.2967/jnumed.124.267665

BibTeX
@article{Demirci2024,
  author = {Demirci, Ridvan Arda and Gulati, Roman and Hawley, Jessica E and Yezefski, Todd and Haffner, Michael C and Cheng, Heather H and Montgomery, Robert B and Schweizer, Michael T and Yu, Evan Y and Nelson, Peter S and Chen, Delphine L and Iravani, Amir},
  title = {SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  pages = {jnumed.124.267665},
  doi = {10.2967/jnumed.124.267665}
}
Kostenlos starten →